J&J is already seeing strong sales growth for its treatment-resistant depression (TRD) and MDD therapy Spravato (esketamine), ...

Big data is transforming this approach by providing healthcare organisations with a deeper understanding of patient ...

The results of the Intuition Brain Health study – sponsored by Biogen and supported by Apple – show the feasibility of using ...

Neurotech Pharma's cell therapy Encelto has become the first FDA-approved treatment for idiopathic macular telangiectasia ...

Johns Hopkins surgeon and writer Dr Martin Makary, President Donald Trump's pick to lead the FDA, faced a grilling today by ...

The company confirmed this morning that NICE has taken the "unusual decision" to hold a third appraisal committee meeting as ...

The FDA has approved the first generic versions of Johnson & Johnson's big-selling anticoagulant Xarelto, which brought in ...

President Donald Trump's nominee for NIH director, Dr Jay Bhattacharya, fielded intense questioning on vaccines and cuts to ...

Anderson is expecting 2025 to be a pivotal year for his turnaround plan – which revolves around the removal of management ...

Investing in women's health isn't just ethically sound; it's smart business. Women represent half the global population, and ...

pharmaphorum’s digital magazine Deep Dive provides objective, issue-driven views, analysis, high-level interviews and unique ...

In 2023, Roche said it was removing TNKase for stroke from its phase 3 programmes after a readout of the TIMELESS trial, but ...